美国已对来自印度及其他19个特定司法管辖区的某些专科药物及相关成分豁免从价关税。这一豁免措施保护了罕见病和先进疗法，尽管华盛顿正对特定专利进口产品征收高额关税。
The US has exempted certain speciality drugs and related ingredients from ad valorem tariffs for India and 19 other jurisdictions. The carve-out shields rare disease and advanced therapies even as Washington pushes steep duties on specified patented imports.
根据美国商务部发布的通知，美国不会对从印度及其他19个国家进口的某些专科药物及相关成分征收任何从价关税。此举正值华盛顿准备自9月29日起对某些专利药品进口及相关成分征收100%的关税。
The US will not impose any ad valorem tariff on certain speciality drugs and related ingredients imported from India and 19 other countries, according to a notice published by the US Commerce Department. The move comes as Washington prepares to levy a 100 per cent tariff on certain patented pharmaceutical imports and associated ingredients from September 29.
零税率将适用于用于治疗罕见疾病的药物，以及不孕症治疗、细胞疗法、基因疗法、抗体偶联药物和动物用药品。用于这些药物的成分也将符合豁免条件。
The zero per cent rate will apply to products used in the treatment of rare medical conditions, as well as infertility treatments, cell therapies, gene therapies, antibody-drug conjugates and animal pharmaceuticals. Components used in these drugs will also qualify for the exemption.
根据世界海关组织的定义，从价关税是按货物价值的固定百分比征收的税种。商务部表示，由于上述列名司法管辖区与美国现有或即将达成贸易与安全框架协定，其符合条件的产品可享受零关税待遇。
An ad valorem tariff is a tax charged as a fixed percentage of the value of goods, according to the World Customs Organisation. The Commerce Department said the qualifying products from the listed jurisdictions can receive a zero per cent tariff because they have a current or forthcoming trade and security framework agreement with the US.
除印度外，被列入零关税类别的国家和地区包括阿根廷、孟加拉国、柬埔寨、厄瓜多尔、萨尔瓦多、欧盟、危地马拉、印度尼西亚、日本、约旦、马来西亚、北马其顿、韩国、瑞士、列支敦士登、台湾、泰国、英国和越南。
Besides India, the countries and regions placed in the zero-tariff category are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, Britain and Vietnam.
4月2日，唐纳德·特朗普总统发布行政令，对进口美国的专利药品、生物制品及相关成分征收关税，以鼓励国内生产。这些豁免措施是该行政令依据《贸易扩展法》第232条实施的一部分。
On April 2, President Donald Trump issued a proclamation to impose tariffs on imports of patented pharmaceuticals, biologics and associated ingredients into the US as part of efforts to encourage domestic production. The exemptions form part of the implementation of that proclamation under Section 232 of the Trade Expansion Act.
该公告规定，对某些特定的专利药品及其成分征收100%的关税。该规定于7月31日对附件中列出的公司生效，而对其他受影响的公司则从9月29日起开始实施。
The proclamation imposed a 100 per cent tariff on specified patented pharmaceuticals and ingredients. It took effect on July 31 for companies named in one annex and will apply to other covered companies from September 29.
美国商务部的通知还指出，仿制药及其相关成分不受第232条规定的药品关税的影响。该通知对原公告进行了几处技术性修改，包括重新定义“仿制药”一词，以明确将其范围扩展至未获得专利的动物保健产品；同时明确说明“药品”仅指成品药品、其活性成分以及这些成分的关键起始原料。
The Commerce Department notice also said generic pharmaceutical products and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs. It made several technical corrections to the original proclamation, including revising the definition of generic pharmaceutical articles to specifically include unpatented animal health products, and clarifying that pharmaceutical articles cover only finished pharmaceutical products, their active pharmaceutical ingredients and the key starting materials of such ingredients.
实际上，尽管美国对某些专利药品的进口征收高额关税，但它仍豁免了某些特殊药品及其成分针对印度及其他19个地区的从价关税。（信息来源：PTI）
In effect, the US has exempted certain speciality drugs and their components from ad valorem tariffs for India and 19 other jurisdictions, even as it moves ahead with steep tariffs on specified patented pharmaceutical imports. With PTI Inputs